Endo International PLC (ENDP) Given Daily Coverage Optimism Rating of 0.06
Media coverage about Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Endo International PLC earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.1697368351691 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Remarkable Stock News Analysis: Endo International plc (NASDAQ:ENDP), Sanchez Energy Corporation (NYSE:SN … – Market Breaking Point (press release) (journalfinance.net)
- Endo International plc (ENDP)- Stocks worth Investment with Performance Assessment – NASDAQ Times (nasdaqtimes.com)
- INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm (finance.yahoo.com)
- Breakfast Technical Briefing on Drug Makers Stocks — Amarin, Endo, Ionis Pharma, and Teva Pharma (bizjournals.com)
- Endo International PLC (ENDP) Expected to Announce Quarterly Sales of $780.75 Million (americanbankingnews.com)
Shares of Endo International PLC (ENDP) traded down 2.324% during midday trading on Thursday, reaching $8.615. The company had a trading volume of 2,764,361 shares. The firm’s 50 day moving average price is $8.69 and its 200-day moving average price is $10.64. The stock’s market capitalization is $1.92 billion. Endo International PLC has a 1-year low of $7.41 and a 1-year high of $21.87.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.86 EPS. Equities research analysts expect that Endo International PLC will post $3.52 EPS for the current fiscal year.
Several analysts have issued reports on ENDP shares. Canaccord Genuity set a $12.00 target price on Endo International PLC and gave the stock a “hold” rating in a research note on Thursday, June 8th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Endo International PLC in a research report on Thursday, June 8th. Stifel Nicolaus downgraded Endo International PLC from a “buy” rating to a “hold” rating and lowered their price objective for the company from $22.00 to $15.00 in a research report on Friday, June 9th. Royal Bank Of Canada set a $15.00 price objective on Endo International PLC and gave the company a “hold” rating in a research report on Monday, June 12th. Finally, William Blair reiterated a “market perform” rating on shares of Endo International PLC in a research report on Wednesday, June 14th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $12.80.
In other news, CFO Blaise Coleman bought 6,500 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was acquired at an average cost of $7.89 per share, with a total value of $51,285.00. Following the transaction, the chief financial officer now directly owns 13,729 shares in the company, valued at approximately $108,321.81. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Terrance J. Coughlin bought 20,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were purchased at an average cost of $7.70 per share, with a total value of $154,000.00. Following the completion of the transaction, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 36,000 shares of company stock valued at $279,460. 0.50% of the stock is currently owned by corporate insiders.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.